IS2750B - Leiðarafesting - Google Patents

Leiðarafesting

Info

Publication number
IS2750B
IS2750B IS6329A IS6329A IS2750B IS 2750 B IS2750 B IS 2750B IS 6329 A IS6329 A IS 6329A IS 6329 A IS6329 A IS 6329A IS 2750 B IS2750 B IS 2750B
Authority
IS
Iceland
Prior art keywords
compounds
conductor mount
formula
racemate
tautomer
Prior art date
Application number
IS6329A
Other languages
English (en)
Other versions
IS6329A (is
Inventor
Gunnar Hedlund
Karl Jansson
Stig Joensson
Anders Bjoerk
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9903838A external-priority patent/SE9903838D0/xx
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of IS6329A publication Critical patent/IS6329A/is
Publication of IS2750B publication Critical patent/IS2750B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IS6329A 1999-10-25 2002-04-02 Leiðarafesting IS2750B (is)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US16140799P 1999-10-25 1999-10-25
SE9903838A SE9903838D0 (sv) 1999-10-25 1999-10-25 Novel compounds
US21281600P 2000-06-21 2000-06-21
SE0002320A SE0002320D0 (sv) 1999-10-25 2000-06-21 Malignant tumors
PCT/SE2000/002055 WO2001030758A1 (en) 1999-10-25 2000-10-24 Drugs for the treatment of malignant tumours

Publications (2)

Publication Number Publication Date
IS6329A IS6329A (is) 2002-04-02
IS2750B true IS2750B (is) 2011-08-15

Family

ID=27484521

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6329A IS2750B (is) 1999-10-25 2002-04-02 Leiðarafesting

Country Status (21)

Country Link
EP (1) EP1224172B1 (is)
JP (1) JP3950337B2 (is)
KR (2) KR100674160B1 (is)
AT (1) ATE358668T1 (is)
AU (1) AU775057B2 (is)
CA (1) CA2386775C (is)
CZ (1) CZ298534B6 (is)
DE (1) DE60034240T2 (is)
DK (1) DK1224172T3 (is)
EE (1) EE200200207A (is)
ES (1) ES2280258T3 (is)
HK (1) HK1049830A1 (is)
HR (1) HRP20020353A2 (is)
HU (1) HU229072B1 (is)
IL (2) IL148782A0 (is)
IS (1) IS2750B (is)
NO (1) NO323320B1 (is)
NZ (1) NZ518296A (is)
SE (1) SE0002320D0 (is)
UA (1) UA73748C2 (is)
WO (1) WO2001030758A1 (is)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314124B2 (en) 2004-02-06 2012-11-20 Active Biotech Ab Crystalline salts of quinoline compounds and methods for preparing them
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SE0401578D0 (sv) * 2004-06-18 2004-06-18 Active Biotech Ab Novel compounds
MX341797B (es) 2004-06-24 2016-09-02 Vertex Pharmaceuticals Incorporated * Moduladores de transportadores con casete de union con atp.
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
DK1937642T3 (en) 2005-10-19 2014-12-15 Teva Pharma Crystals of sodium laquinimod and the process for its preparation
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
EA018031B1 (ru) 2006-06-12 2013-05-30 Тева Фармасьютикал Индастриз, Лтд. Стабильные препараты лаквинимода
KR100916160B1 (ko) * 2007-02-21 2009-09-08 (주)바이오버드 약제학적 항암 조성물
EP2065380A1 (en) * 2007-08-22 2009-06-03 F.Hoffmann-La Roche Ag Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer
PT2682120T (pt) 2007-12-20 2016-11-07 Teva Pharma Preparações de laquinimod estáveis
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
WO2010028015A2 (en) 2008-09-03 2010-03-11 Auspex Pharmaceuticals, Inc 2-oxo-1,2-dihydro-quinoline modulators of immune function
MX384179B (es) 2009-03-20 2025-03-14 Vertex Pharma Proceso para producir moduladores del regulador de conductancia transmembrana de fibrosis quística.
US8962598B2 (en) * 2010-10-14 2015-02-24 Immunahr Ab 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as AHR activators
US8802700B2 (en) 2010-12-10 2014-08-12 Vertex Pharmaceuticals Incorporated Modulators of ATP-Binding Cassette transporters
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
JP2015511583A (ja) 2012-02-27 2015-04-20 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 薬学的組成物およびその投与
MX2015005632A (es) * 2012-11-07 2016-02-05 Teva Pharma Sales de amina de laquinimod.
WO2014153145A2 (en) 2013-03-14 2014-09-25 Teva Pharmaceutical Industries Ltd. Crystals of laquinimod sodium and improved process for the manufacture thereof
MX366837B (es) * 2014-09-23 2019-07-26 Active Biotech Ab Quinolinas carboxamidas para usarse en el tratamiento de mielomas multiples.
EP3204358B1 (en) 2014-10-07 2018-09-19 Vertex Pharmaceuticals Incorporated Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator
MX379401B (es) * 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
JP7223998B2 (ja) 2017-10-13 2023-02-17 小野薬品工業株式会社 Ａｘｌ阻害剤を有効成分として含む固形がん治療剤
WO2021105117A1 (en) * 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
ES3032708T3 (en) 2020-03-03 2025-07-23 Active Biotech Ab Tasquinimod or a pharmaceutically acceptable salt thereof for use in combination therapy
US20230203003A1 (en) * 2020-05-21 2023-06-29 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
KR20230133317A (ko) 2021-01-18 2023-09-19 액티브 바이오테크 에이비 골수이형성 증후군의 치료에 이용하기 위한 타스퀴니모드또는 이의 약제학적으로 허용가능한 염
AU2022281056A1 (en) 2021-05-25 2023-11-30 Active Biotech Ab A plurality of tasquinimod particles and use thereof
CA3221689A1 (en) 2021-07-02 2023-01-05 Hans Wannman A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product
TWI838849B (zh) 2021-09-13 2024-04-11 美商美國禮來大藥廠 Ahr促效劑
AR126963A1 (es) 2021-09-13 2023-12-06 Lilly Co Eli Agonistas de ahr
CA3241699A1 (en) * 2021-12-20 2023-06-29 The Johns Hopkins University Compounds for treatment of cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52670B1 (en) * 1981-03-03 1988-01-20 Leo Ab Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation
GB9108547D0 (en) * 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
GB9404378D0 (en) * 1994-03-07 1994-04-20 Fujisawa Pharmaceutical Co Quinoline derivatives
GB2290786A (en) * 1994-06-30 1996-01-10 Fujisawa Pharmaceutical Co Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6121287A (en) * 1998-07-15 2000-09-19 Active Biotech Ab Quinoline derivatives
SE9802549D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE9802550D0 (sv) * 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives

Also Published As

Publication number Publication date
NO20021932D0 (no) 2002-04-24
IL148782A (en) 2007-05-15
AU775057B2 (en) 2004-07-15
HRP20020353A2 (en) 2005-10-31
HU229072B1 (en) 2013-07-29
CZ298534B6 (cs) 2007-10-31
AU1185101A (en) 2001-05-08
HK1049830A1 (zh) 2003-05-30
DE60034240T2 (de) 2007-12-20
NO20021932L (no) 2002-06-21
JP2003512454A (ja) 2003-04-02
IS6329A (is) 2002-04-02
KR100674160B1 (ko) 2007-01-24
NO323320B1 (no) 2007-03-12
CA2386775A1 (en) 2001-05-03
HUP0203238A2 (hu) 2003-01-28
EP1224172A1 (en) 2002-07-24
EP1224172B1 (en) 2007-04-04
SE0002320D0 (sv) 2000-06-21
KR20020043646A (ko) 2002-06-10
WO2001030758A1 (en) 2001-05-03
IL148782A0 (en) 2002-09-12
NZ518296A (en) 2003-06-30
EE200200207A (et) 2003-06-16
DE60034240D1 (de) 2007-05-16
ATE358668T1 (de) 2007-04-15
DK1224172T3 (da) 2007-08-13
JP3950337B2 (ja) 2007-08-01
KR100597938B1 (ko) 2006-07-06
CZ20021293A3 (cs) 2002-07-17
ES2280258T3 (es) 2007-09-16
KR20060054496A (ko) 2006-05-22
CA2386775C (en) 2004-07-13
UA73748C2 (en) 2005-09-15
HUP0203238A3 (en) 2003-05-28

Similar Documents

Publication Publication Date Title
IS2750B (is) Leiðarafesting
YU23202A (sh) Lekovi za tretman malignih tumora
BR0209431A (pt) Novos compostos de 4-anilinoquinolino-3-carboxamidas
DE60030741D1 (de) Chinazoline verbindungen als heilmittel
DK1519724T3 (da) Fredericamycin-derivater som lægemidler til behandling af tumorer
SE9904505D0 (sv) Novel compounds
PL367682A1 (en) Dolastatin 10 derivatives
SE0103836D0 (sv) Novel compounds
DK1200412T3 (da) Antiproliferative imidazolforbindelser
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE316083T1 (de) Adamantanderivate
GB0112348D0 (en) Compounds
SE0101932D0 (sv) Pharmaceutical combinations
NO20043016L (no) 6-aminomorfinan-derivater, fremgangsmate for fremstilling og anvendelse derav
SE9903894D0 (sv) Novel compounds
JO2390B1 (en) Diphenylcarboxamides act as lipid-lowering agents
SE0101038D0 (sv) Novel compounds
MXPA04005809A (es) Inhibidores de proteinas quinasas.
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
AU2002248531A1 (en) Pyrazolopyriadine derivatives
SE9904128D0 (sv) Novel compounds
CY1106576T1 (el) Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας
SE0004827D0 (sv) Therapeutic compounds
PE20030236A1 (es) Derivados de bencimidazol 1-aril-2-n,s- u o-sustituidos, obtencion de medicamentos y preparados farmaceuticos que contienen estos derivados